DiaMedica Therapeutics Inc.DMACNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
10.56%
↓ 84% below average
Average (39q)
64.81%
Historical baseline
Range
High:2063.30%
Low:-92.57%
CAGR
-5.1%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | 10.56% |
| Q2 2025 | 2.93% |
| Q1 2025 | -12.58% |
| Q4 2024 | 29.84% |
| Q3 2024 | 26.86% |
| Q2 2024 | 6.86% |
| Q1 2024 | -0.03% |
| Q4 2023 | 12.38% |
| Q3 2023 | 28.67% |
| Q2 2023 | -29.71% |
| Q1 2023 | 59.38% |
| Q4 2022 | 38.41% |
| Q3 2022 | -16.11% |
| Q2 2022 | -0.96% |
| Q1 2022 | 5.51% |
| Q4 2021 | -19.77% |
| Q3 2021 | 8.16% |
| Q2 2021 | -10.39% |
| Q1 2021 | -22.88% |
| Q4 2020 | 44.58% |
| Q3 2020 | 34.88% |
| Q2 2020 | 18.61% |
| Q1 2020 | -25.14% |
| Q4 2019 | 11.44% |
| Q3 2019 | -13.71% |
| Q2 2019 | -28.12% |
| Q1 2019 | 8.27% |
| Q4 2018 | 134.53% |
| Q3 2018 | -1.21% |
| Q2 2018 | 2063.30% |
| Q1 2018 | -92.57% |
| Q4 2017 | 31.86% |
| Q3 2017 | -46.30% |
| Q2 2017 | -21.12% |
| Q1 2017 | 173.14% |
| Q4 2016 | -42.82% |
| Q3 2016 | 101.11% |
| Q2 2016 | 53.74% |
| Q1 2016 | -9.17% |
| Q4 2015 | 80.08% |